You just read:

TapImmune's HER2/neu-Targeted Breast Cancer Vaccine to be Studied in a Large Phase 2 Immunotherapy Combination Study Funded by an $11 Million U.S. Department of Defense Grant

News provided by

TapImmune Inc.

Oct 10, 2018, 06:30 ET